{
    "Clinical Trial ID": "NCT00490646",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV",
        "  trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.",
        "INTERVENTION 2: ",
        "  Trastuzumab 2 mg/kg + Docetaxel 100 mg/m^2 IV",
        "  trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Locally advanced or metastatic HER2+ breast cancer not previously treated with chemotherapy or trastuzumab.",
        "  Subjects who had received prior (neo)adjuvant chemotherapy or trastuzumab were eligible except if they relapsed within 12 months after the last dose of a taxane or trastuzumab given as (neo)adjuvant therapy.",
        "  Measurable disease",
        "  Left Ventricular Ejection Fraction (LVEF) 50%",
        "Exclusion Criteria:",
        "  Prior chemotherapy or trastuzumab for metastatic breast cancer (MBC)",
        "  Relapse within 1 year after (neo)adjuvant taxane or trastuzumab",
        "  Neuropathy > Grade 1",
        "  Significant cardiovascular disease",
        "  Any brain metastases"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Objective Response (OR; Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)",
        "  Percentage of participants with best overall response (BOR) of either complete response (CR) or partial response (PR) according to RECIST version 1.1 as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all lesions. CR and PR criteria should be met again after 4 weeks and before 6 weeks after initial assessment. A two-sided confidence interval (CI) was computed using the Clopper-Pearson method.",
        "  Time frame: Assessed every 6 weeks from initiation of study therapy up to 12 months; then every 3 months until disease progression (maximum time that any participant was on therapy was 108 weeks)",
        "Results 1: ",
        "  Arm/Group Title: Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV",
        "  Arm/Group Description: trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 25",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  60.0        (38.7 to 78.9)",
        "Results 2: ",
        "  Arm/Group Title: Trastuzumab 2 mg/kg + Docetaxel 100 mg/m^2 IV",
        "  Arm/Group Description: trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 25",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  52.0        (31.3 to 72.2)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 13/24 (54.17%)",
        "  FEBRILE NEUTROPENIA 5/24 (20.83%)",
        "  HAEMATOTOXICITY 0/24 (0.00%)",
        "  NEUTROPENIA 3/24 (12.50%)",
        "  LYMPHADENOPATHY 0/24 (0.00%)",
        "  PERICARDIAL EFFUSION 1/24 (4.17%)",
        "  ATRIAL FIBRILLATION 1/24 (4.17%)",
        "  APLASIA 0/24 (0.00%)",
        "  NAUSEA 0/24 (0.00%)",
        "  PYREXIA 1/24 (4.17%)",
        "  EXTRAVASATION 0/24 (0.00%)",
        "  CHOLECYSTITIS 1/24 (4.17%)",
        "  PATHOLOGICAL FRACTURE 1/24 (4.17%)",
        "Adverse Events 2:",
        "  Total: 6/24 (25.00%)",
        "  FEBRILE NEUTROPENIA 0/24 (0.00%)",
        "  HAEMATOTOXICITY 1/24 (4.17%)",
        "  NEUTROPENIA 0/24 (0.00%)",
        "  LYMPHADENOPATHY 1/24 (4.17%)",
        "  PERICARDIAL EFFUSION 0/24 (0.00%)",
        "  ATRIAL FIBRILLATION 0/24 (0.00%)",
        "  APLASIA 1/24 (4.17%)",
        "  NAUSEA 1/24 (4.17%)",
        "  PYREXIA 0/24 (0.00%)",
        "  EXTRAVASATION 1/24 (4.17%)",
        "  CHOLECYSTITIS 0/24 (0.00%)",
        "  PATHOLOGICAL FRACTURE 0/24 (0.00%)"
    ]
}